When a company keeps repeating that its flagship weedkiller is “safe when used as directed,” you don’t expect it to quietly set aside another €1 billion just to deal with lawsuits.
But that’s exactly what Bayer has done.
This brings the total amount earmarked for Roundup litigation to nearly €7 billion — money reserved purely for handling cancer claims and other legal fallout from glyphosate-based weedkillers.
Seven billion euros is not a rounding error.
It’s a signal.
So the real question becomes:
What does a number like that actually tell us?
Bayer’s Growing Roundup Lawsuit Problem
Bayer’s purchase of Monsanto in 2018 wasn’t just a business transaction — it was the moment they inherited one of the most expensive and long-running legal battles in modern corporate history.
And that battle hasn’t slowed. It’s grown.
As of mid-October 2025, Bayer reported:
- 197,000 registered claims since litigation began
- 132,000 cases settled or ineligible
- 65,000 unresolved cases and rising
What’s even more interesting is the trend:
New filings increased after the last major settlement round.
Normally, settlements help close a chapter. Yet in this case, they’ve only encouraged more people to come forward.
If the science is “settled,” as regulators like to say, why are so many people still stepping into court?
If Roundup Is Safe, Why Does Bayer Keep Adding to Its Lawsuit Fund?
This is the contradiction at the centre of the Roundup story.
Bayer continues to insist glyphosate-based weedkillers are safe.
Regulators continue to repeat the same line.
Marketing continues to lean on familiar language about safety “when used as directed.”
And yet… Bayer keeps topping up a litigation reserve worth more than the GDP of some countries.
Companies don’t casually set aside billions unless they expect future payouts.
They certainly don’t do it for a product that’s supposedly risk-free.
So what exactly is driving Bayer to prepare for years of ongoing litigation?
Is it the science?
The testimony?
The evidence emerging in courtrooms?
Or the growing public awareness that something isn’t adding up?
Roundup Lawsuit Filings Are Still Rising
Bayer’s CEO recently told investors he’s “confident” litigation risk will be “significantly contained” by 2026. On paper, that sounds encouraging.
But the numbers don’t match the optimism.
- Claims are still being added.
- New plaintiffs continue stepping forward.
- The cost of settlements keeps rising.
And every time Bayer announces progress, another wave of filings appears.
If these cases were fading, the reserve fund would shrink.
Instead, Bayer just increased it by another €1 billion.
That tells us something important:
The company is preparing for more.
Regulators Say Roundup Is Safe — But Courts Keep Disagreeing
This is one of the most striking contradictions in the entire debate.
In New Zealand, regulators still treat glyphosate-based weedkillers as low-risk.
The messaging hasn’t changed in years.
Officials emphasise correct use, low toxicity, and minimal danger.
But the courtroom experience overseas paints a very different picture:
- Juries have repeatedly ruled for plaintiffs.
- Courts have found Bayer/Monsanto failed to warn about potential risks.
- Regulators’ safety assumptions have not held up under litigation.
So why do New Zealand regulators continue to rely on a safety model that keeps collapsing under legal scrutiny overseas?
It’s a question worth asking — especially after New Zealand’s 30 October decision to keep most Maximum Residue Limits (MRLs) unchanged for now, while raising dry field peas to 6mg/kg. The pause doesn’t change the bigger picture: glyphosate-based formulations are still used widely, and the pressure to increase MRLs could resurface at any time.
What Bayer’s €7 Billion Roundup Provision Really Shows
Let’s step back for a moment and look at the scale:
€7 billion
= NZD ~$12.6 billion
= more than our entire annual Police, Justice, and Courts budgets combined
= a staggering amount of money to reserve for one chemical
Corporations don’t set aside sums like this unless they expect to pay them out.
And they don’t expect to pay them out unless there is significant, ongoing risk.
The numbers tell a story regulators haven’t.
Roundup isn’t a minor liability.
It’s a major one — large enough to shift financial strategies, restructure divisions, and reshape investor confidence.
If a product is genuinely safe, you don’t build a €7 billion legal cushion to defend it.
Why Bayer’s Roundup Litigation Matters for New Zealand
This isn’t an American issue.
It’s a global one — and New Zealand is not insulated from global trends.
Here’s why it matters here:
- We use glyphosate-based weedkillers everywhere — on roadsides, parks, orchards, school grounds, backyards.
- Our regulators rely on outdated assessments that don’t reflect modern findings about endocrine disruption, microbiome impacts, oxidative stress, or formulation toxicity.
- We rarely test our own food, water, or soil for glyphosate or AMPA.
- New Zealand courts have never been forced to confront the evidence, because we don’t have a single Roundup cancer case here.
- We are aligning ourselves with the regulators — and not the evidence.
When the rest of the world is litigating the risks, and we’re still treating glyphosate-based weedkillers as benign, what are we missing?
And more importantly — who carries the cost if they’re wrong?
What This Roundup Litigation Tells Us About Real-World Risk
Roundup’s courtroom record may not be a scientific study, but it is evidence.
It tells us:
- people exposed to glyphosate-based weedkillers believe they were harmed
- their stories were compelling enough for juries to agree
- judges found that warnings were inadequate
- thousands of cases had enough merit for Bayer to settle
- the number of new claims continues to grow
When a company is forced to defend health claims case after case, year after year, the message becomes clear:
Real-world use doesn’t always match regulatory assumptions.
And that should concern us — especially in a country that uses these products so freely.
Where This Roundup Litigation Story Leaves New Zealand
Here’s the uncomfortable truth:
Bayer is preparing for years more of litigation.
Its investors expect it.
Its financial statements reflect it.
Its growing reserve fund confirms it.
Meanwhile, New Zealand’s regulatory system still assumes everything is under control.
No mandatory chemical residue reporting.
No independent testing of glyphosate-based formulations.
No consideration of long-term or low-dose risks.
No updated assessments that reflect modern toxicology.
If Bayer must plan for billions more in payouts, maybe we should ask why our own regulators aren’t planning for anything at all.
We’re told Roundup is safe.
But the courts disagree.
The numbers disagree.
The growing list of plaintiffs disagree.
And Bayer’s €7 billion lawsuit fund?
That might be the clearest message of all.
Resources & References
Bayer’s Latest Litigation Provision (2025)
Summary of Bayer’s additional €1bn allocation for Roundup-related lawsuits.
https://www.ofimagazine.com/news/bayer-sets-aside-another-1bn-us-1-15bn-for-us-glyphosate-lawsuits
Why Glyphosate Isn’t Just a Weed Killer — It’s a Public Health Issue
A look at how glyphosate-based weedkillers affect far more than weeds — including soil health, water contamination, and potential long-term impacts on human wellbeing.
https://nomoreglyphosate.nz/why-glyphosate-isnt-just-a-weed-killer/
Bayer’s Billion-Dollar Problem: What the Roundup Lawsuits Reveal
A detailed look at the many global lawsuits against Bayer for glyphosate-based weedkillers, how this litigation began, major verdicts, and the evolving legal landscape.
https://nomoreglyphosate.nz/bayer-legal-woes-roundup-lawsuits/
Are Glyphosate-Based Weedkillers Safe?
A breakdown of Grok’s safety analysis and what it reveals about the gaps in regulatory assumptions, real-world exposure, and product formulation risks.
https://nomoreglyphosate.nz/are-glyphosate-weedkillers-safe-2025/
Further Reading
Whitewash — Carey Gillam’s Monsanto Exposé
A deep dive into Carey Gillam’s investigation of Monsanto’s influence over science, regulation, and public perception. This review explores how decades of corporate shaping helped build the myth of glyphosate’s safety.
https://nomoreglyphosate.nz/whitewash-carey-gillam-monsanto-expose/
Toxic Legacy — Stephanie Seneff’s Glyphosate Examination
A review of Stephanie Seneff’s controversial but thought-provoking book connecting glyphosate exposure to rising chronic health issues. This piece unpacks the research, the debate, and why her arguments still resonate today.
https://nomoreglyphosate.nz/toxic-legacy-stephanie-seneff-review/
The Monsanto Papers — Inside the Glyphosate Legal Battle
This review explores The Monsanto Papers, the behind-the-scenes story of the Roundup trials that exposed internal emails, industry strategies, and the evidence juries relied on when ruling against Monsanto.
https://nomoreglyphosate.nz/the-monsanto-papers-glyphosate-legal-battle/
Image Source & Attribution
We’re grateful to the talented photographers and designers whose work enhances our content. The feature image on this page is by taldav68.
